

9705 890-3

ATMP's copy



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 43/40, C07D 413/00, 251/58, 207/00, 405/00, 333/74, 333/64		A1	(11) International Publication Number: WO 96/39833
			(43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/09161		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 4 June 1996 (04.06.96)			
(30) Priority Data: 08/485,317 7 June 1995 (07.06.95)		US	
(60) Parent Application or Grant (63) Related by Continuation US Filed on 08/485,317 (CON) 7 June 1996 (07.06.96)		Published With international search report.	
(71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only): BOWLING, Nancy, L. [US/US]; 101 White Oak Drive, Greenfield, IN 46140 (US).			
(74) Agents: STRODE, Janelle, D. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).			
(54) Title: MODULATION OF CALCIUM CHANNELS			
(57) Abstract			
A method for modulating calcium channels, increasing the density of calcium channels in vascular and cardiac tissue with no changes in inotropic or pressor response, comprising administering to a warm-blooded animal in need thereof a pharmaceutically-effective amount of a compound having formula (I) wherein R¹ and R³ are independently hydrogen, C₁-C₄ alkyl, -CO-(C₁-C₆ alkyl), or -CH₂Ar, -CO-Ar, wherein Ar is phenyl or substituted phenyl; R² is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically-acceptable salt thereof.			
(I)			